Glioma Market Overview
A glioma is a central nervous system tumor that arises from glial stem or progenitor cells. Glial cells are a type of cell widely present in the nervous system. Gliomas mainly occur in the brain and, rarely, in the spinal cord.
Glioma Epidemiology Insights (2022)
- The Total Glioma incident cases in the United States were ~19K cases in 2022
- Glioblastoma contributed to the highest number of glioma cases
- Around 36% cases were contributed by 60–74 years age group
- Grade IV accounted for the highest number of incident cases
Glioma Epidemiology Segmentation in the US from 2019 to 2032
- Total Incident Population
- Grade-specific Incident Population
- Type-specific Population of High-grade Glioma
- Type-specific Population of Low-grade Glioma
- Age-specific Population
- Glioma Cases Based on Molecular Alterations
Glioma Market Insight (2022)
The Glioma Market size in the US was valued ~USD 600 million in 2022
Glioma Market Strengths
- Rise in the aging population
- Improvement in genomics and proteomics
Glioma Market Opportunities
- Increasing incidence trend
- Substantial market opportunity for key players
Glioma Emerging Drugs and Key Companies
- Regorafenib: Bayer
- ONC201: Chimerix
- AV-GBM-1: Aivita Biomedical
- Enzastaurin (DB-102): Denovo Biopharma
- DCVax-L: Northwest Therapeutics
- Ofranergene Obadenovec (VB-111): VBL Therapeutics
- LAM561 (2-OHOA): Laminar Pharmaceuticals
- MEDI4736 (durvalumab): MedImmune
- Tasadenoturev (DNX-2401): DNAtrix
- ITI-1000 (pp65 DC Vaccine): Immunomic Therapeutics
- IGV-001: Imvax
- SurVaxM: MimiVax
- Berubicin: CNS Pharmaceuticals
- GLIOVAC (Sitoiganap): Epitopoietic Research Corporation (ERC)
- Lerapolturev + Pembrolizumab: Istari Oncology
- SONALA-001 + Exablate 2.0 Device: SonALAsense
- VAL-083 (dianhydrogalactitol): Kintara Therapeutics
- Pomalidomide: Bristol Myers Squibb
- MDNA55: Medicenna Therapeutics
- BMX-001: BioMimetix
- Lenvatinib ± Pembrolizumab: Eisai and Merck Sharp & Dohme
- Paxalisib (GDC-0084): Kazia Therapeutics
- OKN-007: Oblato
- Temferon: Genenta Science
- EO2401: Enterome
- INO-5401+ INO-9012+ LIBTAYO (cemiplimab): Inovio Pharmaceuticals
- Selinexor (KPT-330): Karyopharm Therapeutics
- VBI-1901: VBI Vaccines
- NOX-A12 (Olaptesed Pegol): TME Pharma
- Tovorafenib (DAY101): Day One Biopharmaceuticals
- Vorasidenib (AG-881): Servier
- Eflornithine: Orbus Therapeutics
- TVI-Brain-1: TVAX Biomedical
- AB-218: AnHeart Therapeutics
- BGB-290: Beigene
- Mirdametinib: SpringWorks Therapeutics
- FT-2102 (Olutasidenib): Forma Therapeutics
- Vinblastine + Bevacizumab: Hoffmann-La Roche
- Cobimetinib: Hoffmann-La Roche
- PEMAZYRE (Pemigatinib): Incyte Corporation
- VERZENIO (abemaciclib): Eli Lilly, and others